|Bid||0.0000 x 1800|
|Ask||0.0000 x 1000|
|Day's Range||1.6300 - 1.8000|
|52 Week Range||1.1600 - 5.4800|
|Beta (5Y Monthly)||-0.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 14, 2022 - Nov 18, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.75|
Subscribe to Yahoo Finance Plus to view Fair Value for GMTX
At three years old, an Atlas Venture spinout focused on blood disorders is going public by merging with another local biotech company.
WAYLAND, Mass. & WATERTOWN, Mass., August 10, 2022--Gemini Therapeutics, Inc. (Nasdaq: GMTX) ("Gemini") and Disc Medicine, Inc. ("Disc"), a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Disc’s pipe
Even if it's not a huge purchase, we think it was good to see that Braden Leonard, a Gemini Therapeutics, Inc...